Real-world vinflunine outcomes in bladder cancer in a single-institution study: moving beyond clinical trials

G Moriceau, A Vallard, R Rivoirard, B Méry… - Clinical genitourinary …, 2015 - Elsevier
Purpose Intravenous vinflunine 320 mg/m 2 every 3 weeks plus best supportive care
resulted in better overall survival in comparison with best supportive care alone for eligible …
被引用次数：8 相关文章

Real-World Vinflunine Outcomes in Bladder Cancer in a Single-Institution Study: Moving Beyond Clinical Trials

G Moriceau, A Vallard… - Clinical …, 2015 - clinical-genitourinary-cancer.com
Purpose Intravenous vinflunine 320 mg/m 2 every 3 weeks plus best supportive care
resulted in better overall survival in comparison with best supportive care alone for eligible …

Real-World Vinflunine Outcomes in Bladder Cancer in a Single-Institution Study: Moving Beyond Clinical Trials

G Moriceau, A Vallard, R Rivoirard… - Clinical …, 2015 - pubmed.ncbi.nlm.nih.gov
Purpose Intravenous vinflunine 320 mg/m (2) every 3 weeks plus best supportive care
resulted in better overall survival in comparison with best supportive care alone for eligible …

Real-World Vinflunine Outcomes in Bladder Cancer in a Single-Institution Study: Moving Beyond Clinical Trials.

G Moriceau, A Vallard, R Rivoirard, B Méry… - Clinical Genitourinary …, 2015 - europepmc.org
Purpose Intravenous vinflunine 320 mg/m (2) every 3 weeks plus best supportive care
resulted in better overall survival in comparison with best supportive care alone for eligible …

Real-World Vinflunine Outcomes in Bladder Cancer in a Single-Institution Study: Moving Beyond Clinical Trials

G Moriceau, A Vallard, R Rivoirard, B Méry… - Clinical Genitourinary …, 2015 - infona.pl
Intravenous vinflunine 320 mg/m2 every 3 weeks plus best supportive care resulted in better
overall survival in comparison with best supportive care alone for eligible patients with …